History
2024 - 2018
Y2023 Licensed out AL101-AMD for wet AMD to Hanlim Pharm
Y2022 Completed Phase 2a clinical trial for AL101-MASH
¡¡¡¡¡¡Completed Phase 2 clinical trial for AL101-AMD
¡¡¡¡¡¡Completed Phase 2 clinical trial for AL102-PDTY2019 ~ Y2021 V.C. funding 8.5 billion KRW
Y2019 Signed a MOU on PASylation technology with XL-protein
¡¡¡¡¡¡Received the Korea Industry Grand Prize in Biotechnology Award from Money Today
¡¡¡¡¡¡Received the Korea KONEX Award for Best Technology by the Korea ExchangeY2018 Launched sales of Ob-X on home-shopping channels
2017-2010
Y2016 Listed in KONEX
Y2013 ~ Y2016 V.C. funding 12 billion KRW
Y2015 AL101-AMD Phase 2 IND approved
Y2012 Started sales of Ob-X in Korea and overseas
Y2010 Ob-X approved as a functional ingredient with health claim by MFDS
2009-2004
Y2009 Completed Phase 2 clinical trial of AL101-AOB for abdominal obesity
Y2007 Awarded INNO-BIZ certification by the SMBA (Small and Medium Business Administration)
Y2006 Attracted capital from the KDB (Korea Development Bank) for technology development
Y2005 Selected as an 'Excellent Company' by the Korea Technology and Credit Guarantee Agency
Y2004 ~ Y2009 Awarded numerous research grants from the Ministry of Health & Welfare and the SMBA for developing new drugs
2003-1999
Y2000 Research center was certified
Y1999 Recognized as a start-up with good technology